Trends and determinants in reimbursement decision-making in Poland in the years 2013–2015

Abstract

Our study revealed a fair agreement between the AOTMiT recommendations and the MoH decisions; the association was especially weak in 2015.

Shedding light on the HTA consultancy market: Insights from Poland

“…Our research contributes to the literature on stakeholder involvement in HTA [45][46][47] by demonstrating that the scope of stakeholders in HTA to consider is broader and may include private-sector companies. Further, in contrast to studies focusing on later stages of the HTA process, especially the discussions held by appraisal committees, here we point to the less visible stage of technology assessment [28][29][30]36], which has so far largely escaped research attention.…”

“…Consistent reliance on this model of HTA in Poland has created conditions for the emergence of consultancy firms assisting manufacturers in preparing country-specific HTA reports based on the AHTAPol's guidelines. Third, as HTA and the reimbursement processes are interconnected and some staff in HTA consultancy firms have worked for public institutions involved in drug reimbursement, HTA consultancies are uniquely positioned to advise manufacturers on the broader regulatory environment [19,20], which has evolved significantly since the early 2000s [28,29]. Fourth, as Poland is an important European pharmaceutical market there are a steady number of drugs applying for HTA appraisals annually ranging from approximately 80 to 100 [28,29].…”

“…Third, as HTA and the reimbursement processes are interconnected and some staff in HTA consultancy firms have worked for public institutions involved in drug reimbursement, HTA consultancies are uniquely positioned to advise manufacturers on the broader regulatory environment [19,20], which has evolved significantly since the early 2000s [28,29]. Fourth, as Poland is an important European pharmaceutical market there are a steady number of drugs applying for HTA appraisals annually ranging from approximately 80 to 100 [28,29]. This, too, is a good proxy for a strong demand for services provided by HTA consultancy firms.…”

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries

“…The example of such country is the Netherlands, where no drugs have been excluded from coverage because of their unfavorable cost-effectiveness (Carrera and IJzerman, 2016). Governments may decide to reimburse orphan drugs despite a negative recommendation, if they constitute the only therapeutic option for a selected group of patients (Kawalec et al, 2018).…”